Psychedelic Research

The American Alternative Care Policy Network (AACPN) this week launched its Psychedelic Research Initiative to support continued scientific research into emerging therapies that may help address some of America's most difficult mental health challenges. At the center of this effort are veterans. For many veterans, the invisible wounds of service can persist long after they return home. Post-traumatic stress, depression, anxiety, traumatic brain injury, substance-use disorders

AACPN applauds Connecticut’s enactment of Public Act 26-108, expanding the state’s psychedelic-assisted therapy pilot program and supporting continued clinical research involving MDMA and psilocybin therapies for veterans, first responders, trauma survivors, and individuals living with treatment-resistant mental health conditions.

AACPN welcomes the U.S. Department of Veterans Affairs’ launch of a clinical trial evaluating MDMA-assisted therapy for veterans living with PTSD and alcohol use disorder. The organization says rigorous scientific research is essential to understanding whether emerging therapies can safely and effectively support veterans and other trauma survivors facing complex behavioral health challenges.

The U.S. Department of Veterans Affairs has launched a new MDMA-assisted therapy clinical trial focused on veterans with PTSD and trauma-related conditions. The initiative reflects growing interest in evidence-based psychedelic-assisted therapies and broader efforts to expand innovative mental health treatment options for veterans and other trauma survivors.

The American Alternative Care Policy Network (AACPN) welcomes the unanimous passage of Louisiana legislation establishing a state-backed psychedelic-assisted therapy research initiative focused on mental health and substance-use disorders. The legislation reflects growing bipartisan recognition that treatment-resistant mental illness, PTSD, addiction, and veteran suicide require continued exploration of evidence-informed therapeutic innovation and expanded clinical research.

The proposal would create a state initiative for clinical studies involving ibogaine and psilocybin

The American Alternative Care Policy Network (AACPN) today announced its launch, establishing a policy-driven platform to accelerate the integration of evidence-based alternative therapies into the U.S. healthcare system—where they can deliver measurable outcomes, expand access, and reduce long-term costs. AACPN enters a fragmented and often unserious policy environment with a clear mandate: impose rigor, elevate standards, and translate validated therapies into actionable le